How would you approach a young patient with a local recurrence that now has Her2 positive disease?

Topics: Breast Cancer • Medical Oncology

If a patient previously received taxane-based chemotherapy for ER/PR+ Her2 negative disease three years ago, is additional chemotherapy recommended at recurrence or can Her2-directed and hormonal therapy be sufficient? Would you use combination therapy with trastuzumab + pertuzumab or trastuzumab alone?

Answer from: Medical Oncologist at Academic Institution

For Her-2 positive disease, I would definitely choose chemotherapy with anti Her-2 agent(s). With Her-2 positivity and a young age, the patient is at high risk for recurrence which can be significantly reduced by the addition of anti Her-2 agents to chemotherapy. Although this is a local recurrence,...

Comments

Medical Oncologist at Onc San Antonio
Very helpful. Similar scenario: Ipsilateral recu...

Related Questions